Robyn Karnauskas
Stock Analyst at Truist Securities
(1.93)
# 3,178
Out of 5,127 analysts
177
Total ratings
43.79%
Success rate
-0.26%
Average return
Main Sectors:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $1,025.00 | +15.32% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $3.17 | +215.96% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $364.65 | -18.28% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $60.86 | +6.80% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $117.15 | -6.10% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $147.23 | -43.63% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $222.44 | -5.59% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.35 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $188.99 | +79.90% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.01 | +2,487.06% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $2.12 | +230.19% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $754.91 | +50.35% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.73 | +478.03% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.64 | +240.91% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $27.35 | -15.90% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $26.81 | +79.04% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $20.78 | +140.62% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $463.48 | +9.61% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $27.61 | +30.39% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $72.07 | -65.31% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.66 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $59.66 | +134.66% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $2.23 | +1,345,191.48% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.09 | +542.20% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $24.71 | +122.58% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $7.69 | +4,061.25% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $23.33 | -35.71% | 5 | Aug 9, 2022 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $1,025.00
Upside: +15.32%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $3.17
Upside: +215.96%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $364.65
Upside: -18.28%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $60.86
Upside: +6.80%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $117.15
Upside: -6.10%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $147.23
Upside: -43.63%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $222.44
Upside: -5.59%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.35
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $188.99
Upside: +79.90%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.01
Upside: +2,487.06%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $2.12
Upside: +230.19%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $754.91
Upside: +50.35%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.73
Upside: +478.03%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.64
Upside: +240.91%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $27.35
Upside: -15.90%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $26.81
Upside: +79.04%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $20.78
Upside: +140.62%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $463.48
Upside: +9.61%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $27.61
Upside: +30.39%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $72.07
Upside: -65.31%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.66
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $59.66
Upside: +134.66%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $2.23
Upside: +1,345,191.48%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.09
Upside: +542.20%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $24.71
Upside: +122.58%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $7.69
Upside: +4,061.25%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $23.33
Upside: -35.71%